MMG-1 |
|
Vaxjo ID |
292 |
|
Vaccine Adjuvant Name |
MMG-1 |
|
Alternative Names |
MMG-1 is also known as a monomycoloyl glycerol analogue, used as an immunostimulatory lipid. |
|
Adjuvant VO ID |
VO_0005657
|
|
Description |
MMG-1 is a synthetic analogue of a mycobacterial lipid, incorporated into nanocarriers to enhance immune responses. MMG-1 is also known as a monomycoloyl glycerol analogue, used as an immunostimulatory lipid. |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
the immunopotentiator monomycoloyl glycerol-1 (MMG-1) |
|
Structure |
The formulation consists of phytantriol and MMG-1, forming hexosomes with inverse hexagonal (HII) structure. |
|
Appearance |
It appears as nanosized, hexagonally-structured particles visualized by cryo-TEM. |
|
Storage |
It is stored at room temperature for up to one week, with further stability not specified. |
|
Preparation |
Preparation involves lipid melting, mixing with poloxamer in PBS, and ultrasonication to form hexosomes. |
|
Dosage |
The vaccine dose in mice was 200 uL containing 5ug of antigen and 0.484 mmol/mL of immunostimulatory lipid. |
|
Function |
The liposome-based vaccine formulation induced a much stronger MOMP-specific cell-mediated immune response compared to hexosome-adjuvanted MOMP, which elicited minimal MOMP-specific T-cell stimulation after vaccination. Hence, our data demonstrates that hexosomal and liposomal adjuvants activate the immune system via different mechanisms. Our work provides valuable insights into the adjuvant potential of hexosomes and emphasizes that engineering of the supramolecular structure can be used to design adjuvants with customized immunological properties. |
|
Safety |
Safety was confirmed in vitro and in vivo, showing no significant toxicity at tested doses. |
| References |
Rodrigues et al., 2018: Rodrigues L, Raftopoulos KN, Tandrup Schmidt S, Schneider F, Dietz H, Rades T, Franzyk H, Pedersen AE, Papadakis CM, Christensen D, Winter G, Foged C, Hubert M. Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of controlled release : official journal of the Controlled Release Society. 2018; 285; 12-22. [PubMed: 29964134].
|
